Point State Capital LP Dynavax Technologies Corp Transaction History

Point State Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$8.14 - $13.28 $10.7 Million - $17.5 Million	-1,316,800 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$11.85 - $16.0 $6.77 Million - $9.15 Million	-571,700 Reduced 30.27%	1,316,800 $16.3 Million
Q2 2018 Aug 14, 2018	BUY	$15.15 - $20.75 $28.6 Million - $39.2 Million	1,888,500 New	1,888,500 $28.8 Million
Q1 2018 May 15, 2018	SELL	$14.65 - $19.9 $5.04 Million - $6.85 Million	-344,364 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$17.3 - $24.08 $15 Million - $20.9 Million	-867,336 Reduced 71.58%	344,364 $6.44 Million
Q3 2017 Nov 14, 2017	SELL	$15.2 - $21.5 $2.86 Million - $4.05 Million	-188,300 Reduced 13.45%	1,211,700 $26.1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,400,000	1,400,000 $13.5 Million

275

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.61B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.